PCSK9 and Hypercholesterolemia: Thus, generally speaking, apheresis can be considered in hypercholesterolaemia other than homozygous FH if atherosclerotic vascular disease is present and progressive and if LDL-C treatment goals, which vary from country to country, are not met despite maximal possible drug therapy (including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors).